Navellier & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Navellier & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,427	Closed	-$4.6M	–	376
2024 Q4	$4.6M	Buy	11,427 +395	+4%	+$183K	0.55%	44
2024 Q3	$5.13M	Sell	11,032 -669	-6%	-$321K	0.7%	33
2024 Q2	$5.48M	Sell	11,701 -160	-1%	-$69.4K	0.64%	33
2024 Q1	$4.96M	Sell	11,861 -537	-4%	-$227K	0.61%	41
2023 Q4	$5.04M	Buy	12,398 +568	+5%	+$210K	0.76%	34
2023 Q3	$4.11M	Buy	+11,830	New	+$4.14M	0.7%	37

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Navellier & Associates's VRTX Position: Q1 2025 in Review

Navellier & Associates sold out of Vertex Pharmaceuticals (VRTX) in Q1 2025, closing a stake of 11,427 shares — an estimated $4.6M sold.

Navellier & Associates first reported a position in VRTX in Q3 2023 and held it in 6 quarters. The position peaked at $5.48M in Q2 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Navellier & Associates reported no remaining Vertex Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Navellier & Associates sold 11,427 Vertex Pharmaceuticals shares in Q1 2025, an estimated $4.6M.
Navellier & Associates first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Navellier & Associates's Vertex Pharmaceuticals position peaked at $5.48M in Q2 2024.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Navellier & Associates's 13F filing for Q1 2025, filed 6 May 2025.